|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013|
|Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Park|
|Cancer Research and Treatment. 2018;50(3):757-767. Published online 2017 September 4 DOI: https://doi.org/10.4143/crt.2017.050|
Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
P-66 Trend of lung cancer in recent 5 years; Analysis as viewed from age, gender, pathological types, stage of disease, therapeutic modality, and prognosis
190 Tolvaptan – cost effective treatment of SIADH in malignancies
A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis
47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?
Staging of lung cancer: A cost-effectiveness analysis
Cost analysis of hospital treatment—two chemotherapic regimens for non-surgical non-small cell lung cancer
O-12 The cost effectiveness (CE) and cost to medicare of gefitinib (Iressa; ZD1839) for the third-line treatment of non-small cell lung cancer (NSCLC): Can medicare afford the bill?
Chemotherapy benefit and cost-effectiveness of treatment for advanced lung cancer
Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer
|This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.|